Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6998523 | 0.86 | KDM4E (0.51) | KDM4ELMNAALDH1A1HPGDGLA | |
| SCHEMBL12553458 | 0.86 | KDM4E (0.57) | KDM4ELMNAALDH1A1HPGDGLA | |
| SCHEMBL11363863 | 0.86 | KDM4E (0.51) | KDM4ELMNAALDH1A1HPGDGLA | |
| SCHEMBL8575822 | 0.78 | KDM4E (0.42) | KDM4ELMNAALDH1A1HPGDGAA | |
| SCHEMBL1029836 | 0.77 | KDM4E (0.67) | KDM4ELMNAGAACYP19A1MAPT | |
| SCHEMBL78687 | 0.76 | ACHE (0.53) | KDM4ELMNAALDH1A1HPGDACHE | |
| SCHEMBL31162811 | 0.76 | ACHE (0.53) | KDM4ELMNAALDH1A1HPGDACHE | |
| SCHEMBL30487578 | 0.74 | MAOA (0.62) | KDM4ELMNAALDH1A1HPGDGLA | |
| SCHEMBL698750 | 0.73 | KDM4E (1.00) | KDM4ELMNAALDH1A1HPGDGAA | |
| SCHEMBL30294185 | 0.73 | KDM4E (1.00) | KDM4ELMNAALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266887-B1 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-08-17 | — | — | EP | disclosed |
| US-6844445-B2 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2005-01-18 | — | — | US | disclosed |
| US-6627650-B2 | An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. | LES LABORATOIRES SERVIER (FR) | 2003-09-30 | — | — | US | disclosed |
| EP-1245565-B1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-09-24 | — | — | EP | disclosed |
| EP-1241169-B1 | Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-08-27 | — | — | EP | disclosed |
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | LES LABORATOIRES SERVIER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1266887-A2 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | disclosed |
| US-6465660-B1 | PARTICULARLY 2-HYDROXY-8,9-DIMETHOXYISOINDOLO(2,1-A)INDOL-6-ONE AND 2-HYDROXY-8,9-DIMETHOXYISOINDOLO(2,1-A)INDOL-6-ONE; TREATING A DISORDER OF THE MELATONINERGIC SYSTEM | LES LABORATOIRES SERVIER (FR) | 2002-10-15 | — | — | US | disclosed |
| EP-1245565-A1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-10-02 | — | — | EP | disclosed |
| EP-1241169-A1 | Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-09-18 | — | — | EP | disclosed |
| US-4032656-A | ANTIPROSTAGLANDIN ACTIVITY, ANTIDIARRHEA AGENTS | SMITHKLINE CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | IDO1, IDO2, AHR | KDM4E 2363/4885LMNA 3971/4885ALDH1A1 115/4885 |
| US-20020173531-A1 | Indenoindolone compounds | MTNR1A, MTNR1B, CYP11B1 | KDM4E 3234/4885LMNA 2106/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.